HPV infections and immunosuppression

Clinics in Dermatology

Volumn 15, Issue 3, 1997, Pages 427-437

  Bouwes Bavinck, Jan N ^a   Berkhout, Ron J M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETRETINATE; HLA B27 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; RETINOIC ACID; RETINOID; VIRUS DNA;

ACTINIC KERATOSIS; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LIP CARCINOMA; MELANOMA; PRIORITY JOURNAL; REVIEW; SKIN CARCINOMA; SUN EXPOSURE; TOPICAL DRUG ADMINISTRATION; UTERINE CERVIX CARCINOMA; VERRUCA VULGARIS; WART VIRUS;

EID: 0030786497     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(96)00154-X     Document Type: Article

References (155)

1. Boyle J, MacKie RM, Briggs JD, et al. Cancer, warts, and sunshine in renal transplant recipients: a case-control study. Lancet 1984;1:702-5.
2. Bouwes Bavinck JN, de Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129:242-9.
3. Barr BBB, Benton EC, McLaren K, et al. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989;1:124-9.
4. Rüdlinger R, Smith IW, Bunney MH, et al. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681-92.
5. IARC. Human papillomaviruses. Lyon, France: IARC Scientific Publications, 1995.
6. Berkhout RJM, Tieben LM, Smits HL, et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995;33:690-5.
7. de Jong-Tieben LM, Berkhout RJM, Smits HL, et al. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol 1995;105:367-71.
8. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996;88:802-11.
9. Burk RD, Kadish AS. Treasure hunt for human papillomaviruses in nonmelanoma skin cancers. J Natl Cancer Inst 1996;88:781-2.
10. Hartevelt MM, Bouwes Bavinck JN, Kootte AMM, et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990;49:506-9.
11. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, et al. Relation between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991;325:843-8.
12. Hardie IR. Skin cancer in transplant recipients. Transplant Rev 1995;9:1-17.
13. Dyall-Smith D, Trowell H, Mark A, et al. Cutaneous squamous cell carcinomas and papillomaviruses in renal transplant recipients: a clinical and molecular biological study. J Dermatol Sci 1991;2:139-46.
14. Gassenmaier A, Fuchs P, Shell H, et al. Papillomavirus DNA in warts of immunosuppressed renal allograft recipients. Arch Dermatol Res 1986;278:219-23.
15. van der Leest RJ, Zachow KR, Ostrow RS, et al. Human papillomavirus heterogeneity in 36 renal transplant recipients. Arch Dermatol 1987;123:354-7.
16. Hardie IR, Strong RW, Hartley LCJ, et al. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980;87:177-83.
17. Glover MT, Niranjan N, Kwan JTC, et al. Non-melanoma skin cancer in renal transplant recipients: extent of the problem and a strategy for management. Br J Plast Surg 1994;47:86-9.
18. London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995;346:403-6.
19. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996;61:715-21.
20. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the nordic countries. Int J Cancer 1995;60:183-9.
21. Ferrándiz C, Fuente MJ, Ribera M, et al. Epidermal dysplasia and neoplasia in kidney transplant recipients. J Am Acad Dermatol 1995;33:590-6.
22. Bouwes Bavinck JN, Robertson I, Wainwright RW, et al. Excessive skin cancers and pre-malignant skin lesions in an Australian heart-transplant recipient. Br Heart J 1995; 74:468-70.
23. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995;33: 222-9.
24. Espana A, Redondo P, Fernández AL, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995; 32:458-65.
25. Mihalow ML, Gattuso P, Abraham K, et al. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplantation 1996;10:248-55.
26. Orth G. Epidermodysplasia verruciformis. In: Salzman NP, Howley PM, editors. The Papovaviridae, the papillomaviruses. New York: Plenum, 1987:199-243.
27. Copper KD, Androphy EJ, Lowy D, et al. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990;94:769-76.
28. Pfister H. Human papillomavirus and skin cancer. Semin Cancer Biol 1992;3:263-71.
29. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995;131:1312-8.
30. Euvrard S, Chardonnet Y, Pouteil-Noble CP, et al. Skin malignancies and human papillomaviruses in renal transplant recipients. Transpl Proc 1993;25:1392-3.
31. Euvrard S, Chardonnet Y, Pouteil-Noble C, et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. Cancer 1993;72:2198-206.
32. Shamanin V, Glover M, Rausch C, et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 1994;54:4610-3.
33. Stark LA, Arends MJ, McLaren KM, et al. Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumour promotion. Br J Cancer 1994;69:222-9.
34. Soler C, Chardonnet Y, Allibert P, et al. Detection of mucosal human papillomavirus types 6/11 in cutaneous lesions from transplant recipients. J Invest Dermatol 1993;101:286-91.
35. Soler C, Chardonnet Y, Euvrard S, et al. Evaluation of human papillomavirus type 5 on frozen sections of multiple lesions from transplant recipients with in situ hybridization and non-isotopic probes. Dermatology 1992; 184:248-53.
36. Trenfield K, Salmond CA, Pope JH, et al. Southern blot analysis of skin biopsies for human papillomavirus DNA: renal allograft recipients in South-Eastern Queensland. Aust J Dermatol 1993;34:71-8.
37. McGregor JM, Farthing A, Crook T, et al. Posttransplant skin cancer: a possible role for p53 gene mutation but not for oncogenic human papillomaviruses. J Am Acad Dermatol 1994;30:701-6.
38. Goldberg LH, Griego RD. Absence of human papillomavirus in squamous cell carcinoma of nongenital skin from immunocompromised renal transplant patients. Arch Dermatol 1995;131:107-8.
39. Höpfl R, Petter A, Pfister A. Human papillomavirus in nonmelanoma skin cancer? The phylogenetic tree of the papillomavirus family is not yet complete. Arch Dermatol 1996;132:834.
40. Bouwes Bavinck JN, Gissmann L, Claas FHJ, et al. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. J Immunol 1993;151:1579-86.
41. King GN, Healy CM, Dent B, et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 1995;332:1052-7.
42. Regev E, Zeltser R, Lustmann J. Lip carcinoma in renal allograft recipient with long-term immunosuppressive therapy. Oral Surg Oral Med Oral Pathol 1992;73:412-4.
43. Thomas DW, Seddon SV, Shepherd JP. Systemetic immunosuppression and oral malignancy: a report of a case and review of the literature. Br J Oral Maxillofacial Surg 1993;31:391-3.
44. Kawashima M, Favre M, Obalek S, et al. Premalignant lesions and cancers of the skin in the general population: evaluation of the role of human papillomaviruses. J Invest Dermatol 1990;95:537-42.
45. Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatim and squamous neoplasia of the cervix. Acta Cytol 1983;27:220-4.
46. Alloub MI, Barr BBB, McLaren KM, et al. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. Br Med J 1989;298:153-6.
47. Kelly GE, Sheil AGR, Rose BR, et al. HPV infection in the lower genital tract of women undergoing hemodialysis and women with renal allografts. Clin Transplant 1991; 5:7-12.
48. Euvrard S, Kanitakis J, Chardonnet Y, et al. External anogenital lesions in organ-transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol (in press).
49. Fairley CK, Sheil AGR, McNeil JJ, et al. The risk of anogenital malignancies in dialysis and transplant patients. Clin Nephrol 1994;41:101-5.
50. Greene MH, Young TI, Clark WH. Malignant melanoma in renal transplant recipients. Lancet 1981;1:1196-9.
51. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-8.
52. Green A, Swerdlow AJ. Epidemiology of melanocytic nevi. Epidemiol Reviews 1989;11:204-21.
53. Garbe C, Büttner P, Weiß J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the central malignant melanoma registry of the German dermatological society. J Invest Dermatol 1994;102:695-9.
54. Barker JNWN, MacDonald DM. Eruptive dysplastic nevi following renal transplantation. Clin Exp Dermatol 1988; 13:123-5.
55. Smith CH, McGregor JM, Barker JNWN, et al. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993;28:51-5.
56. English JSC, Swerdlow AJ, MacKie RM, et al. Relation between phenotype and banal melanocytic naevi. Br Med J 1987;294:152-4.
57. Scheurlen W, Gissmann L, Gross G, et al. Molecular cloning of two new HPV types (HPV 37 and HPV 38) from a keratoacanthoma and a malignant melanoma. Int J Cancer 1986;37:505-10.
58. Bouwes Bavinck JN, Crijns M, Vermeer BJ, et al. Chronic sun exposure and age are inversely associated with nevi in adult renal transplant recipients. J Invest Dermatol 1996;106:1036-41.
59. Bouwes Bavinck JN, Kootte AMM. Kaposi's sarcoma in a renal transplant recipient. Br J Dermatol 1989;121:805-6.
60. Tappero JW, Conant MA, Wolfe SF, et al. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993;28:371-95.
61. Civati G, Busnach G, Brando B, et al. Occurrence of Kaposi's sarcoma in renal transplant recipients treated with low doses of cyclosporine. Transplant Proc 1988;20 (Suppl 3):924-8.
62. Burke GW, Jordan MC, Simmons RL, et al. Recurrent Kaposi's sarcoma in a renal transplant recipient: regression following treatment of cytomegaloviremia with ganciclovir. Clin Transplant 1993;7:491-5.
63. Shmueli D, Shapira Z, Yussim A, et al. The incidence of Kaposi sarcoma in renal transplant patients and its relation to immunosuppression. Transplant Proc 1989;21: 3209-10.
64. Studniberg HM, Rivers JK, Cooke BE, et al. The coexistence of lymphangiosarcoma and Kaposi's sarcoma in a renal transplant recipient. Cancer 1991;68:2330-35.
65. Touraine JL, Gamier JL, Lefrancois N, et al. Severe lymphoproliferative disease and Kaposi sarcoma in transplant patients. Transplant Proc 1989;21:3197-8.
66. Bencini PL, Marchesi L, Cainelli T, et al. Kaposi's sarcoma in kidney transplant recipients treated with cyclosporin. Br J Dermatol 1988;118:709-14.
67. Penn I, Brunson ME. Cancers after cyclosporine therapy. Transplant Proc 1988;20(suppl 3):885-92.
68. Huang YQ, Li JJ, Rush MG, et al. HPV-16-related DNA sequences in Kaposi's sarcoma. Lancet 1992;339:515-8.
69. Scinicariello F, Rady P, Cloyd MW, et al. HPV 18 in HIV-associated Kaposi's sarcoma. Lancet 1991;337:501.
70. Biggar RJ, Dunsmore N, Kurman RJ, et al. Failure to detect human papillomavirus in Kaposi's sarcoma. Lancet 1992;339:1604-5.
71. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpes-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
72. Roizman B. New viral footprints in Kaposi's sarcoma. N Engl J Med 1995;332:1227-8.
73. Levy JA. A new human herpesvirus: KSHV or HHV8? Lancet 1995;346:786.
74. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346:799-802.
75. Huang YQ, Li JJ, Kaplan MH, et al. Human herpesviruslike nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995;345:759-61.
76. Boshoff C, Whitby D, Hatziioannou T, et al. Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 1995;345:1043-4.
77. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995;332:1181-5.
78. Dupin N, Grandadam M, Calvez V, et al. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 1995;345:761-2.
79. Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J 1988; 296:13-7.
80. Vitaliano PP, Urbach F. The relative importance of risk factors in nonmelanoma carcinoma. Arch Dermatol 1980; 116:454-6.
81. Marks R. Squamous cell carcinoma. Lancet 1996;347:735-8.
82. Green A, Beardmore G, Hart V, et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988;19: 1045-52.
83. Karakas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. JAMA 1992;267:3305-10.
84. Armstrong BK, Kricker A. Skin cancer. Dermatol Clin 1995;13:583-94.
85. Blohmé I, Larkö O. Premalignant and malignant lesions in renal transplant recipients. Transplantation 1984;37:165-7.
86. Kelly GE, Mahony JF, Shell AGR, et al. Risk factors for skin carcinogenesis in immunosuppressed kidney transplant recipients. Clin Transplant 1987;1:271-7.
87. Taylor AEM, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol (Stockh) 1992;72:115-9.
88. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986;122:1288-93.
89. Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994;8:388-95.
90. Roeger LS, Sheil AGR, Disney APS, et al. Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients. Clin Transplantation 1992;6:202-11.
91. Shuttleworth D, Marks R, Griffin PJA, et al. Epidermal dysplasia and cyclosporine therapy in renal transplant recipients: a comparison with azathioprine. Br J Dermatol 1989;120:551-4.
92. Lennard L, Thomas S, Harrington CI, et al. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985;113:723-9.
93. Marks R, Jolley D, Lectsas S, et al. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust 1990; 152:62-6.
94. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88: 10124-8.
95. Nakazawa H, English D, Randell PL, et al. UV and skin cancer: Specific p53 gene mutations in normal skin as a biological relevant exposure measurement. Proc Natl Acad Sci USA 1994;91:360-4.
96. McGregor JM, Berkhout RJM, Rozycka M, et al. P53 mutations implicate sunlight and, possibly, DNA replication errors in post-transplant non-melanoma skin cancer (submitted).
97. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
98. Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841-51.
99. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71.
100. Kripke ML. Ultraviolet radiation and immunology: something new under the sun - presidential address. Cancer Res 1994;54:6102-5.
101. Jeevan A, Kripke ML. Ozone depletion and the immune system. Lancet 1993;342:1159-60.
102. Pamphilon DH, Alnaqdy AA, Wallington TB. Immunomodulation by ultraviolet light: clinical studies and biological effects. Immunol Today 1991;12:119-23.
103. Mommaas AM, van Praag MCG, Bouwes Bavinck JN, et al. Analysis of the protective effect of topical sunscreens on the UVB-radiation-induced suppression of the mixed-lymphocyte-reaction. J Invest Dermatol 1990;95:313-6.
104. Cruz PDJ, Bergstresser PR. Ultraviolet radiation, Langerhans' cells, and skin cancer. Conspiracy and failure. Arch Dermatol 1989;125:975-9.
105. Noonan FP, De Fabo EC. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. Immunol Today 1992;13:250-4.
106. Streilein JW. Immunogenetic factors in skin cancer. N Engl J Med 1991;325:884-7.
107. ten Berge RJM, Schellekens PTA, Surachno S, et al. The influence of therapy with azathioprine and prednisone on the immune system of kidney transplant recipients. Clin Immunol Immunopathol 1981;21:20-32.
108. Kelly GE, Sheil AGR, Taylor R. Nonspecific immunological studies in kidney transplant recipients with and without skin cancer. Transplantation 1984;37:368-72.
109. Legendre CM, Guttmann RD, Yip GH. Natural killer cell subsets in long-term renal allograft recipients. A phenotypic and functional study. Transplantation 1986;42:347-52.
110. Klitz W. Viruses, cancer and the MHC. Nature 1992;356: 17-8.
111. Neefjes JJ, Ploegh HL. Intracellular transport of MHC class II molecules. Immunol Today 1992;13:179-84.
112. Monaco JJ. A molecular model of MHC class-I-restricted antigen processing. Immunol Today 1992;13:173-9.
113. Czarnecki D, Zalcberg J, Nicholson I, et al. Skin cancer and HLA antigens. N Engl J Med 1992;326:765.
114. Czarnecki D, Watkins F, Leahy S, et al. Skin cancers and HLA frequencies in renal transplant recipients. Dermatology 1992;185:9-11.
115. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, et al. Skin cancer and HLA antigens. N Engl J Med 1992;326: 766 (reply).
116. Dausset J, Colombani J, Hors J. Major histocompatibility complex and cancer, with special reference to human familial tumors (Hodgkin's disease and other malignancies). Cancer Surv 1982;1:119-17.
117. von Fliedner VE, Sultan-Khan Z, Jeannet M. HLA-DRw antigens associated with acute leukemia. Tissue Antigens 1980;16:399-404.
118. Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, et al. HLA-A11-associated resistance to skin cancer in renal-transplant recipients. N Engl J Med 1990;323:1350 (letter).
119. Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, et al. On a possible protective effect of HLA-A11 against skin cancer and keratotic skin lesions in renal transplant recipients. J Invest Dermatol 1991;97:269-72.
120. Bouwes Bavinck JN, Claas FHJ. The role of HLA molecules in the development of skin cancer. Human Immunol 1994;41:173-9.
121. Glover MT, Bodmer J, Kennedy LJ, et al. HLA antigen frequencies in renal transplant recipients and nonimmunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1993;29A:520-4.
122. McGregor JM, Reddi G, MacDonald D, et al. HLA-A11 in renal allograft recipients with skin cancer. J Invest Dermatol 1992;98:261-2.
123. Bouwes Bavinck JN, Claas FHJ, Hardie DR, et al. Relation between skin cancer and HLA antigens in renal transplant recipients in Queensland, Australia. J Invest Dermatol (in press).
124. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147-51.
125. van Praag MCG, Out-Luiting C, Claas FHJ, et al. Effect of topical sunscreens on the UV-radiation-induced suppression of the alloactivating capacity in human skin in vivo. J Invest Dermatol 1991;97:620-3.
126. Moriarty M, Dunn J, Darragh A, et al. Etretinate in the treatment of actinic keratosis. Lancet 1982;1:364-5.
127. Anonymous. Retinoids and control of cutaneous malignancy. Lancet 1988;2:545-6.
128. Meyskens FL. Coming of age - the chemoprevention of cancer. N Engl J Med 1990;323:825-7.
129. Kraemer KH, DiGiovanna JJ, Moshel AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:1633-7.
130. Kelly JW, Sabto J, Gurr FW, et al. Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991; 338:1407.
131. Shuttleworth D, Marks R, Griffin PJA, et al. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988;68:717-4.
132. Bouwes Bavinck JN, Tieben LM, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal-transplant recipients; a double-blind, placebo-controlled study. J Clin Oncol 1995;13: 1933-8.
133. fa Yuan Z, Davis A, MacDonald K, et al. Use of acitretin for the skin complications in renal transplant recipients. NZ Med J 1995;108:255-6.
134. Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995;59:714-9.
135. Khan MA, Jenkins GR, Tolleson WH, et al. Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes. Cancer Res 1993; 53:905-9.
136. Bartsch D, Boye B, Baust C, et al. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 1992;11:2283-91.
137. McKerrow KJ, MacKie RM, Lesko MJ, et al. The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol 1988;119:313-20.
138. Walker BR, MacKie RM. Serum lipid evaluation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol 1990;122:531-537.
139. Kragballe K, Jansén CT, Geiger J-M, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Acta Derm Venereol (Stockh) 1989;69: 35-40.
140. Mørk NJ, Kolbenstvedt A, Austad J. Efficacy and skeletal side effects of two years' acitretin treatment. Acta Derm Venereol (Stockh) 1992;72:445-8.
141. Euvrard S, Verschoore M, Touraine JL, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992;340:48-9.
142. Scholtens REM, van Zuuren EJ, Posma AN. Treatment of recurrent squamous cell carcinoma of the hand in immunosuppressed patients. J Hand Surg 1995;20A:73-6.
143. van Zuuren EJ, Posma AN, Scholtens REM, et al. Resurfacing of the hand as treatment and prevention of multiple skin cancers in renal transplant recipients. J Am Acad Dermatol 1994;31:760-4.
144. Lobo DV, Chu P, Grekin RC, et al. Nonmelanoma skin cancers and infection with the human immunodefeciency virus. Arch Dermatol 1992;128:623-7.
145. Wang CY, Brodland DG, Su WPD. Skin cancers associated with acquired immunodeficiency syndrome. Mayo Clin Proc 1995;70:766-72.
146. Smith KJ, Skelton HG, Yeager J, et al. Cutaneous neoplasms in a military population of HIV-1-positive patients. J Am Acad Dermatol 1993;29:400-6.
147. Prose NS, von Knebel-Doeberitz C, Miler S, et al. Widespread flat warts associated with human papillomavirus type 5: a cutaneous manifestation of human immunodeficiency virus infection. Am Acad Dermatol 1990;23:978-81.
148. Kang S, Fitzpatrick TB. Debilitating verruca vulgaris in a patient infected with the human immunodeficiency virus. Dramatic improvement with hyperthermia therapy. Arch Dermatol 1994;130:294-6.
149. Chirgwin KD, Feldman J, Augenbraun M, et al. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J Infect Dis 1995; 172:235-8.
150. Melbye M, Coté TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. Lancet 1994;343:636-9.
151. Tosti A, La Placa M, Fanti PA, et al. Human papillomavirus type 16-associated periungual squamous cell carcinoma in a patient with acquired immunodeficiency syndrome. Acta Derm Venereol (Stockh) 1994;74:478-9.
152. Maiman M, Fruchter RG, Guy L, et al. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993;71:402-6.
153. Lewallen S, Shroyer KR, Keyser RB, et al. Aggressive conjunctival squamous cell carcinoma in three young Africans. Arch Ophthalmol 1996;114:215-8.
154. Frazer IH, Tindle RW. Cell-mediated immunity to papillomaviruses. Papillomavirus Rep 1992;3:53-8.
155. Spradbrow PB, Beardmore GL, Francis J. Virions resembling papillomaviruses in hyperkeratotic lesions from sun-damaged skin. Lancet 1983;1:189.